Faculty, Staff and Student Publications
Publication Date
1-1-2023
Journal
OncoImmunology
Abstract
Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.
Keywords
Clinical trials, CTLA-4 blockade, immune checkpoint blockade, next generation immunotherapy, radiation therapy
DOI
10.1080/2162402X.2023.2275333
PMID
37937212
PMCID
PMC10627057
PubMedCentral® Posted Date
November 2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Medical Immunology Commons, Oncology Commons